Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose apatinib + tislelizumab + mXELOX vs tislelizumab + mXELOX in elderly advanced gastric/gastroesophageal junction adenocarcinoma
ChiCTR2500110560Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Oct 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Rivoceranib, tislelizumab, oxaliplatin and capecitabine in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
Rivoceranibtislelizumaboxaliplatincapecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500110560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110560.